Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $12

Larimar Therapeutics, Inc. -2.28% Post

Larimar Therapeutics, Inc.

LRMR

4.72

4.69

-2.28%

-0.64% Post
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ: LRMR) with a Outperform and raises the price target from $11 to $12.